Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.

Clinical trial NCT02000622 · COMPLETED

Trial details

NCT number: NCT02000622
Sponsor: AstraZeneca
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Breast Cancer Metastatic BRCA 1 Gene Mutation BRCA 2 Gene Mutation

Start date: 2014-03-27
Primary completion: 2016-12-09
Enrollment: 302

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.